HF
ACXP icon

HRT Financial’s Acurx Pharmaceuticals ACXP Stock Holding History

HRT Financial’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-718
Closed -$62K – 3012
2021
Q4 		$62K Buy
+718
New +$68.3K ﹤0.01% 2819

Other funds holding ACXP

DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SFA
Semmax Financial Advisors Winston Salem, North Carolina $388M AUM 14.23% 1-Year Est. Return

HRT Financial's ACXP Position: Q1 2022 in Review

HRT Financial sold out of Acurx Pharmaceuticals (ACXP) in Q1 2022, closing a stake of 718 shares — an estimated $62K sold.

HRT Financial first reported a position in ACXP in Q4 2021 and held it in 1 quarter. The position peaked at $62K in Q4 2021. 9 funds tracked by Wall St. Rank hold ACXP as of Q1 2022.

  • HRT Financial reported no remaining Acurx Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • HRT Financial sold 718 Acurx Pharmaceuticals shares in Q1 2022, an estimated $62K.
  • HRT Financial first reported a position in Acurx Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • HRT Financial's Acurx Pharmaceuticals position peaked at $62K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2022.

Based on HRT Financial's 13F filing for Q1 2022, filed 16 May 2022.